Form 4: Denali Therapeutics Director Peter Klein Reports Stock and Option Transactions

Director Peter Klein reported the acquisition of stock and stock options in Denali Therapeutics on May 31, 2024.

Summary

• On May 31, 2024, Peter Klein, a director of Denali Therapeutics Inc., reported transactions involving the company's stock and stock options.
• Klein acquired 5,967 shares of common stock represented by Restricted Stock Units (RSUs) at a price of $0.
• He also acquired 17,901 stock options with an exercise price of $18.56, exercisable starting May 31, 2024, and expiring on May 31, 2034.
• Following these transactions, Klein beneficially owns 21,496 shares of common stock, including 5,967 unvested RSUs, and 17,901 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing detailing transactions. The acquisition of shares and options by a director could be interpreted as a mildly positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment, as insider buying is often seen as a sign of confidence in the company.

Key Dates